|
Zuventus Healthcare Limited, a subsidiary of Emcure Pharmaceuticals, issued a formal clarification on January 16 to address what it termed ‘false and misleading’ communications regarding the company’s future.
The pharmaceutical company felt compelled to act after reports began circulating among trade partners suggesting the company was closing down or rebranding. In a letter signed by chairman Satish Mehta, the firm reassured stakeholders that its operations remain robust and entirely uninterrupted.
The controversy centres on claims that Zuventus had ceased operations or was transitioning its business to an entity called ‘Zorvia Healthcare Limited’. Zuventus has categorically denied any association or affiliation with Zorvia, labelling such suggestions as wholly false. The company maintains that these rumours are a calculated exercise by competitors intended to dilute its brand value and exploit its long-standing market reputation.
As a key player in the Indian pharmaceutical industry, Zuventus emphasized its status as a stable ‘going concern’. The company clarified that there has been no closure, suspension, or transfer of its business assets. Furthermore, the company confirmed that all field staff continue to operate at full strength across the country to ensure the seamless distribution and liquidation of goods.
The company utilized this announcement to highlight the continued success of its diverse product portfolio. High-demand brands such as Bevon, Maxtra, Eslo, Augpen, Zinconia, Netromax, Oxyptadil, Tosiban, Troxip, Pegclear, and Brainmax remain under the active manufacture and marketing of Zuventus. According to the letter, these brands enjoy sustained demand and are backed by rigorous quality controls and deep engagement with the medical community.
In addition to maintaining its established lines, Zuventus pointed toward its recent innovations as proof of its operational health. The company recently launched several concept-driven products, including the diabetic treatment Trelaglip, Gutclear Plus Suspension, and Floresp-OX. These launches are framed as evidence of the firm's ongoing investment in research-led innovation and its responsiveness to critical therapeutic needs.
Taking a firm legal stance, Zuventus warned that it is actively pursuing all appropriate remedies under the law to protect its goodwill. The company has reserved the right to initiate both civil and criminal proceedings against any individuals or entities responsible for spreading misinformation. This move signals a zero-tolerance policy toward what the company describes as mischievous conduct by market miscreants.
Stakeholders, including stockists and distributors, have been urged to disregard any communication inconsistent with this official statement. For verified information, the company has designated Jatin Nayyar, the distribution head of the Emcure Group, as the authorized point of contact for all queries. The letter concludes with a commitment to transparency and the protection of the legitimate interests of the pharmaceutical trade.
|